- Home
- MCBS vs PHVS Comparison
MCBS vs PHVS Comparison
Compare MCBS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCBS
- PHVS
- Stock Information
- Founded
- MCBS 2006
- PHVS 2015
- Country
- MCBS United States
- PHVS Netherlands
- Employees
- MCBS N/A
- PHVS N/A
- Industry
- MCBS Major Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- MCBS Finance
- PHVS Health Care
- Exchange
- MCBS Nasdaq
- PHVS Nasdaq
- Market Cap
- MCBS 862.8M
- PHVS 1.0B
- IPO Year
- MCBS 2019
- PHVS 2021
- Fundamental
- Price
- MCBS $33.91
- PHVS $20.35
- Analyst Decision
- MCBS Hold
- PHVS Buy
- Analyst Count
- MCBS 1
- PHVS 6
- Target Price
- MCBS $34.00
- PHVS $35.67
- AVG Volume (30 Days)
- MCBS 41.6K
- PHVS 80.9K
- Earning Date
- MCBS 10-18-2024
- PHVS 11-13-2024
- Dividend Yield
- MCBS 2.71%
- PHVS N/A
- EPS Growth
- MCBS 17.79
- PHVS N/A
- EPS
- MCBS 2.33
- PHVS N/A
- Revenue
- MCBS $135,566,000.00
- PHVS N/A
- Revenue This Year
- MCBS N/A
- PHVS N/A
- Revenue Next Year
- MCBS $3.39
- PHVS N/A
- P/E Ratio
- MCBS $14.55
- PHVS N/A
- Revenue Growth
- MCBS 11.66
- PHVS N/A
- 52 Week Low
- MCBS $19.85
- PHVS $15.00
- 52 Week High
- MCBS $35.79
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- MCBS 60.22
- PHVS 43.75
- Support Level
- MCBS $33.04
- PHVS $19.78
- Resistance Level
- MCBS $35.59
- PHVS $25.40
- Average True Range (ATR)
- MCBS 1.05
- PHVS 1.45
- MACD
- MCBS 0.29
- PHVS -0.53
- Stochastic Oscillator
- MCBS 71.09
- PHVS 9.97
About MCBS MetroCity Bankshares Inc.
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .